Literature DB >> 2228369

Erysipelas.

C Chartier1, E Grosshans.   

Abstract

Mesh：

Year:  1990        PMID： 2228369     DOI： 10.1111/j.1365-4362.1990.tb04833.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  7 in total

1.  Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial.

Authors:  Philippe Bernard; Olivier Chosidow; Loïc Vaillant
Journal:  BMJ       Date:  2002-10-19

2.  Murine model of recurrent group G streptococcal cellulitis: no evidence of protective immunity.

Authors:  A L Bisno; J M Gaviria
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

Review 3.  Cellulitis: A Review of Current Practice Guidelines and Differentiation from Pseudocellulitis.

Authors:  Michelle A Boettler; Benjamin H Kaffenberger; Catherine G Chung
Journal:  Am J Clin Dermatol       Date:  2021-12-13       Impact factor: 7.403

4.  Risk factors associated with local complications of erysipelas: a retrospective study of 152 cases.

Authors:  Hicham Titou; Christelle Ebongo; Elarbi Bouati; Mohammed Boui
Journal:  Pan Afr Med J       Date:  2017-02-05

5.  Risk factors and complications of lower limb cellulitis in Africa: a systematic review.

Authors:  Frank-Leonel Tianyi; Clarence Mvalo Mbanga; Celestin Danwang; Valirie Ndip Agbor
Journal:  BMJ Open       Date:  2018-07-23       Impact factor: 2.692

6.  Liposuction and Controlled Compression Therapy Reduce the Erysipelas Incidence in Primary and Secondary Lymphedema.

Authors:  Tobias Karlsson; Mattias Hoffner; Håkan Brorson
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-05-06

7.  Recurrent erysipelas--risk factors and clinical presentation.

Authors:  Malin Inghammar; Magnus Rasmussen; Adam Linder
Journal:  BMC Infect Dis       Date:  2014-05-18       Impact factor: 3.090
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.